奥拉帕尼
医学
内科学
耐受性
危险系数
不利影响
肿瘤科
中止
临床终点
安慰剂
PARP抑制剂
队列
外科
临床试验
置信区间
病理
生物化学
替代医学
聚合酶
聚ADP核糖聚合酶
基因
化学
作者
Jihong Liu,Rutie Yin,Lingying Wu,Jun Zhu,Ge Lou,Xiaohua Wu,Qi Zhou,Yunong Gao,Beihua Kong,Xin Lu,Jing Wang,Youguo Chen,Ying Cheng,Yueling Wang,Weiguo Lü,Wei Li,Xin Ma,Kate Hsu
摘要
The phase III SOLO2 global study demonstrated the efficacy and safety of maintenance olaparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, in platinum-sensitive relapsed ovarian cancer patients with a BRCA mutation. This separate China cohort of SOLO2 investigated the efficacy and safety of maintenance olaparib in Chinese patients.Patients received olaparib (300 mg twice daily, oral, tablets) or matched placebo. Primary endpoint was investigator-assessed progression-free survival (Response Evaluation Criteria in Solid Tumors version 1.1). Safety and tolerability were also assessed.Thirty-two patients were treated. Olaparib treatment led to an improvement in progression-free survival compared with placebo (hazard ratio = 0.44, 95% confidence interval: 0.17-1.19; median = 13.8 vs. 5.5 months). Results of secondary efficacy endpoints of time to first subsequent treatment/death and time to treatment discontinuation/death were consistent with progression-free survival results. Time to second progression/death and time to second subsequent treatment/death data were immature at data cutoff. The most common adverse events in the olaparib arm were nausea (81.8%), anemia (45.5%), and decreased appetite (36.4%). Grade ≥3 adverse events were experienced by 36.4% of olaparib and 10.0% of placebo patients. No adverse events led to discontinuation of treatment. There were six deaths (olaparib, five; placebo, one); one death in the olaparib arm was due to an unknown cause, all others were related to disease progression.Efficacy and safety findings in the China SOLO2 cohort support the use of olaparib (300 mg twice daily) as maintenance treatment for Chinese patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
科研通智能强力驱动
Strongly Powered by AbleSci AI